Royalty Pharma plc(RPRX)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

RPRX Royalty Pharma plc

休市中 04-17 16:00:00 EDT

32.60

+0.41

+1.27%

盘后32.73

+0.13+0.40%

18:20 EDT

最高32.67	最低32.09	成交量253.73万
今开32.09	昨收32.19	日振幅1.79%
总市值141.26亿	流通市值123.32亿	总股本4.33亿
成交额8,257万	换手率0.67%	流通股本3.78亿
市净率2.03	ROE13.03%	每股收益1.91
52周最高34.20	52周最低24.05	市盈率17.05
股息0.84	股息收益率0.03	ROA4.67%

北京优虎网络科技有限公司

{"stockData":{"symbol":"RPRX","market":"US","secType":"STK","nameCN":"Royalty Pharma plc","latestPrice":32.6,"timestamp":1744920000000,"preClose":32.19,"halted":0,"volume":2537295,"hourTrading":{"tag":"盘后","latestPrice":32.73,"preClose":32.6,"latestTime":"18:20 EDT","volume":34378,"amount":1120680.07,"timestamp":1744928407432},"delay":0,"floatShares":378294982,"shares":433324905,"eps":1.911901,"marketStatus":"休市中","change":0.41,"latestTime":"04-17 16:00:00 EDT","open":32.09,"high":32.665,"low":32.09,"amount":82567725.24003,"amplitude":0.017863,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":1.911901,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1745222400000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1592280000000,"exchange":"NASDAQ","adjPreClose":32.19,"dividendRate":0.025767,"preHourTrading":{"tag":"盘前","latestPrice":32.47,"preClose":32.19,"latestTime":"09:25 EDT","volume":336,"amount":10768.180752,"timestamp":1744896300035},"postHourTrading":{"tag":"盘后","latestPrice":32.73,"preClose":32.6,"latestTime":"18:20 EDT","volume":34378,"amount":1120680.07,"timestamp":1744928407432},"volumeRatio":0.5871223156174892,"impliedVol":0.2554,"impliedVolPercentile":0.5418},"requestUrl":"/m/hq/s/RPRX/tweets","defaultTab":"tweets","newsList":[{"id":"2511692483","title":"Royalty Pharma Plc2024财年实现净利润8.59亿美元，同比减少24.32%","url":"https://stock-news.laohu8.com/highlight/detail?id=2511692483","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2511692483?lang=zh_cn&edition=full","pubTime":"2025-02-15 00:00","pubTimestamp":1739548842,"startTime":"0","endTime":"0","summary":"2月15日，Royalty Pharma Plc公布财报，公告显示公司2024财年净利润为8.59亿美元，同比减少24.32%；其中营业收入为22.64亿美元，同比减少3.86%，每股基本收益为1.92美元。从资产负债表来看，Royalty Pharma Plc总负债78.80亿美元，其中短期债务9.98亿美元，资产负债比为2.32，流动比率为1.44。机构评级：截至2025年2月15日，当前有6家机构对Royalty Pharma Plc目标价做出预测，其中目标均价为40.17美元，其中最低目标价为28.00美元，最高目标价为48.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250215000117abcf1af4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250215000117abcf1af4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["RPRX"],"gpt_icon":0},{"id":"1190995950","title":"Royalty Pharma 2024年第四季度调整后每股收益$1.16超出$1.05的预期，销售额$5.94亿未达到$6.78亿的预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1190995950","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1190995950?lang=zh_cn&edition=full","pubTime":"2025-02-11 20:30","pubTimestamp":1739277028,"startTime":"0","endTime":"0","summary":"Royalty Pharma报告季度每股收益为$1.16，超过分析师一致预期的$1.05，增幅为10.48%。公司报告季度销售额为$5.94亿，未达到分析师一致预期的$6.78亿，相差12.50%。与去年同期销售额$5.96亿相比，下降了0.34%。以上内容来自Benzinga Earnings专栏，原文如下：Royalty Pharma  reported quarterly earnings of $1.16 per share which beat the analyst consensus estimate of $1.05 by 10.48 percent. This is a 0.87 percent increase over earnings of $1.15 per share from the same period last year.  The company reported quarterly sales of $594.00 million which missed the analyst consensus estimate of $678.89 mil","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Royalty Pharma 2024年第四季度调整后每股收益$1.16超出$1.05的预期，销售额$5.94亿未达到$6.78亿的预期","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RPRX"],"gpt_icon":0},{"id":"2504449484","title":"特朗普2.0时代即将开启，投资机会如何掘金？","url":"https://stock-news.laohu8.com/highlight/detail?id=2504449484","media":"招商基金","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2504449484?lang=zh_cn&edition=full","pubTime":"2025-01-20 10:36","pubTimestamp":1737340585,"startTime":"0","endTime":"0","summary":"美国候任总统唐纳德·特朗普将于美东时间1月20日12时正式宣誓就任美国第47任总统。特朗普2.0时代即将开启，有哪些投资机会可以布局？值得一提的是，科技股在特朗普任期内表现尤为突出，成为推动美股上涨的主要力量。在特朗普第一个任期内，美元整体表现相对弱势。4年任期内，美元指数累计下跌了10.53%。而纵观全球市场，在特朗普上一任期内，恒生科技指数涨幅超过147%，表现甚至略微优于纳斯达克指数。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250120103318abb12e8e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250120103318abb12e8e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CHRD","DASH","OLED","BRKR","WDC","SNPS","CBSH","GEHC","MDLZ","LNW","TW","RADX","DSGX","FCNCA","ORLY","STLD","GTLB","LIN","JD","PARA","LU0757428866.USD","PCTY","NVMI","DPZ","MNDY","RIVN","ADSK","MARA","BK4585","TCOM","INCY","MTSI","LECO","CCEP","NICE","AVGO","TROW","AMGN","ODFL","FRPT","JBHT","MTCH","ROST","TRMB","DDOG","FTAI","ZM","FOXA","ALNY","CTAS","IDXX","AZN","TTEK","HBAN","MSFT","NTNX","DKNG","FER","ISRG","AAL","LU2065731478.USD","SAIA","TSYW.SI","SBAC","SMCI","RGLD","GMAB","KDP","BK4086","SEIC","BPMC","FWONK","RGEN","WBA","EVRG","MDB","BKNG","KHC","LU1815336091.USD","MMYT","SFM","TER","SOFI","AUR","EXAS","ENPH","TEAM","BK4588","MNST","USJW.SI","RYAAY","CHKP","DLTR","RKLB","RPRX","NBIX","ROKU","NQmain","CWST","FSLR","LNT","HTHT","REG","SBUX","STX","AKAM","FOX","MCHP","AGNC","CG","PODD","LAMR","ANSS","MIDD","CPB","BK4593","PTC","INTC","PDD","FYBR","GILD","NWSA","ON","ADBE","QCOM","QRVO","ULTA","OTEX","ROIV","TSEM","NVDA","AMD","PLTR","LPLA","EA","ROP","PSQ","TSLA","CASY","USAW.SI","HOLX","Z","BPOP","AXON","HST","SRPT","CTSH","SWKS","ICLR","AMZN","ERIE","PNFP","COKE","EXPE","BKR","REGN","FSV","TLN","BK4550","TMUS","FTNT","MKSI","QXO","TECH","ERIC","ALGN","AAON","INTU","ITCI","GLPI","LKQ","MPWR","WWD","ZS","NXPI","EWBC","BK4581","ONC","TTD","BIIB","CEG","CZR","HON","BK4534","GNTX","GEN","QQQ","CHTR","BMRN","NVIW.SI","CME","LSTR","ADI","NFLX","ARM","PCAR","TPG","LI","EBAY","CINF","CSX","QLD","AAPL","CPRT","WTFC","EQIX","BSY","MANH","CSWI","ASML","CRWD","CSGP","CHDN","LU0053671581.USD","NTAP","LOGI","LULU","AFRM","CHRW","NTRS","BK4561","CDNS","LSCC","TQQQ","QID","DOX","ALAB","SSNC","PAA","PEP","DOCU","WYNN","MRVL","FFIV","MKTX","NTRA","AMAT","MRNA","PAYX","TSCO","EXE","COO","PFG","SIRI","COIN","SQQQ","PCVX","APA","COST","MEDP","GRAB","CFLT","META","ARGX","CDW","ESLT","NDAQ","NTES","CYBR","TTWO","NDSN","INSM","FAST","MNQmain","GOOGL",".IXIC","JKHY","AEP","RVMD","ILMN","HOOD","OKTA","MELI","TXN","DUOL","HLNE","HQY","CSCO","HSIC","POOL","ENTG"],"gpt_icon":1},{"id":"2502489855","title":"Royalty Pharma Plc盘中异动 股价大涨5.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2502489855","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2502489855?lang=zh_cn&edition=full","pubTime":"2025-01-10 22:31","pubTimestamp":1736519476,"startTime":"0","endTime":"0","summary":"北京时间2025年01月10日22时31分，Royalty Pharma Plc股票出现异动，股价急速上涨5.00%。Royalty Pharma Plc股票所在的生物技术行业中，整体跌幅为0.32%。Royalty Pharma Plc公司简介：Royalty Pharma PLC 是生物制药特许权使用费最大的买家。Royal Pharma 收取超过 35 种商业产品的特许权使用费，包括艾伯维和强生的 Imbruvica、Biogen 的 Tysabri、Vertex 的囊性纤维化特许经营权和 10 个开发阶段的候选产品。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250110223116a21d0d6b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250110223116a21d0d6b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","RPRX"],"gpt_icon":0},{"id":"2483385635","title":"Royalty Pharma Plc2024财年第三财季实现净利润5.44亿美元，同比增加654.40%","url":"https://stock-news.laohu8.com/highlight/detail?id=2483385635","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2483385635?lang=zh_cn&edition=full","pubTime":"2024-11-15 00:01","pubTimestamp":1731600115,"startTime":"0","endTime":"0","summary":"11月15日，Royalty Pharma Plc公布财报，公告显示公司2024财年第三财季净利润为5.44亿美元，同比增加654.40%；其中营业收入为5.65亿美元，同比增加5.41%，每股基本收益为1.22美元。从资产负债表来看，Royalty Pharma Plc总负债77.84亿美元，其中短期债务9.97亿美元，资产负债比为2.32，流动比率为1.54。机构评级：截至2024年11月15日，当前有7家机构对Royalty Pharma Plc目标价做出预测，其中目标均价为41.71美元，其中最低目标价为28.00美元，最高目标价为51.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241115000221abc189fc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241115000221abc189fc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["RPRX"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.royaltypharma.com","stockEarnings":[{"period":"1week","weight":0.0445},{"period":"1month","weight":-0.0242},{"period":"3month","weight":0.0602},{"period":"6month","weight":0.1651},{"period":"1year","weight":0.1807},{"period":"ytd","weight":0.2779}],"compareEarnings":[{"period":"1week","weight":0.0035},{"period":"1month","weight":-0.0617},{"period":"3month","weight":-0.1191},{"period":"6month","weight":-0.0995},{"period":"1year","weight":0.0517},{"period":"ytd","weight":-0.1018}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Royalty Pharma plc于2020年2月6日根据英格兰和威尔士法律注册成立。该公司是生物制药特许权使用费的最大买家，并且是生物制药行业创新的主要资助者。自1996年成立以来，该公司一直是特许权使用费市场的先驱，与来自学术机构，研究医院和非营利组织的创新者（通过中小型生物技术公司到全球领先的制药公司）合作。该公司收集了一系列特许权使用费，使他们有权直接基于许多行业领先疗法的顶线销售进行付款，包括Imbruvica，Januvia，Kalydeco，Trikafta，Truvada，Tysabri和Xtandi。该公司直接或间接地为生物制药行业中的创新提供资金,当他们与公司合作共同资助后期临床试验和新产品上市以换取未来的特许权使用费时，以及当他们从原始创新者那里获得现有的特许权使用费时，就间接地为生物制药行业的创新提供资金。","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":0.03671},{"month":2,"riseRate":0.4,"avgChangeRate":0.004117},{"month":3,"riseRate":0.4,"avgChangeRate":-0.027918},{"month":4,"riseRate":0.6,"avgChangeRate":0.007302},{"month":5,"riseRate":0,"avgChangeRate":-0.050258},{"month":6,"riseRate":0.5,"avgChangeRate":-0.013867},{"month":7,"riseRate":0.6,"avgChangeRate":-0.011556},{"month":8,"riseRate":0.4,"avgChangeRate":-0.016965},{"month":9,"riseRate":0.2,"avgChangeRate":-0.040523},{"month":10,"riseRate":0.4,"avgChangeRate":-0.007226},{"month":11,"riseRate":0.8,"avgChangeRate":0.040135},{"month":12,"riseRate":0.6,"avgChangeRate":0.014047}],"exchange":"NASDAQ","name":"Royalty Pharma plc","nameEN":"Royalty Pharma plc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.33.2","shortVersion":"4.33.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Royalty Pharma plc(RPRX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Royalty Pharma plc(RPRX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Royalty Pharma plc,RPRX,Royalty Pharma plc股票,Royalty Pharma plc股票老虎,Royalty Pharma plc股票老虎国际,Royalty Pharma plc行情,Royalty Pharma plc股票行情,Royalty Pharma plc股价,Royalty Pharma plc股市,Royalty Pharma plc股票价格,Royalty Pharma plc股票交易,Royalty Pharma plc股票购买,Royalty Pharma plc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Royalty Pharma plc(RPRX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Royalty Pharma plc(RPRX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}